A. TITEL

Internationaal Verdrag tegen doping in de sport;

(met Bijlagen en Aanhangsels)

Parijs, 19 oktober 2005

B. TEKST

De Engelse tekst van het Verdrag, met Bijlage II, is geplaatst in Trb. 2006, 194.

Zie voor de Engelse en de Franse tekst van Bijlage I bij het Verdrag, de Lijst van verboden stoffen en methoden – 2005, Trb. 2005, 67.

Zie voor de Engelse en de Franse tekst van de gewijzigde Bijlage I bij het Verdrag, de Lijst van verboden stoffen en methoden – 2006 Trb. 2006, 33.

Zie voor de Engelse en de Franse tekst van de gewijzigde Bijlage I bij het Verdrag, de Lijst van verboden stoffen en methoden – 2008 Trb. 2008, 83.

Zie voor de Engelse en de Franse tekst van de gewijzigde Bijlage I bij het Verdrag, de Lijst van verboden stoffen en methoden – 2009 Trb. 2009, 24.


De Conferentie van Partijen heeft op grond van artikel 34, tweede lid, van het Verdrag, de op 10 mei en 20 september 2008 door het Uitvoerend Comité van het Mondiaal Antidopingagentschap aangenomen wijzigingen van Bijlage II bij het Verdrag goedgekeurd. De Engelse tekst1) van deze wijzigingen luiden als volgt:

ANNEX II
Standards for Granting Therapeutic use Exemptions

Extract from “INTERNATIONAL STANDARD FOR THERAPEUTIC USE EXEMPTIONS” of the World Anti-doping Agency (WADA); in force 1 january 2009

4.0 Criteria for Granting a Therapeutic Use Exemption

A therapeutic use exemption (TUE) may be granted to an Athlete permitting the Use of a Prohibited Substance or Prohibited Method contained in the Prohibited List. An application for a TUE will be reviewed by a Therapeutic Use Exemption Committee (TUEC). The TUEC will be appointed by an Anti-Doping Organization. An exemption will be granted only in strict accordance with the following criteria:

[Comment: This Standard can apply to all Athletes as defined by and subject to the Code, i.e. able-bodied Athletes and Athletes with disabilities. This Standard will be applied according to an individual’s circumstances. For example, an exemption that is appropriate for an Athlete with a disability may be inappropriate for other Athletes.]

  • 4.1 The Athlete should submit an application for a TUE no less than twenty-one (21) days before he/she needs the approval for instance an Event).

  • 4.2 The Athlete would experience a significant impairment to health if the Prohibited Substance or Prohibited Method were to be withheld in the course of treating an acute or chronic medical condition.

  • 4.3 The therapeutic Use of the Prohibited Substance or Prohibited Method would produce no additional enhancement of performance other than that which might be anticipated by a return to a state of normal health following the treatment of a legitimate medical condition. The Use of any Prohibited Substance or Prohibited Method to increase “low-normal” levels of any endogenous hormone is not considered an acceptable therapeutic intervention.

  • 4.4 There is no reasonable therapeutic alternative to the Use of the otherwise Prohibited Substance or Prohibited Method.

  • 4.5 The necessity for the Use of the otherwise Prohibited Substance or Prohibited Method cannot be a consequence, wholly or in part, of prior nontherapeutic Use of any substance from the Prohibited List.

  • 4.6 The TUE will be cancelled by the granting body, if:

    • a. The Athlete does not promptly comply with any requirements or conditions imposed by the Anti-Doping Organization granting the exemption.

    • b. The term for which the TUE was granted has expired.

    • c. The Athlete is advised that the TUE has been withdrawn by the Anti-Doping Organization.

[Comment: Each TUE will have a specified duration as decided upon by the TUEC. There may be cases when a TUE has expired or has been withdrawn and the Prohibited Substance subject to the TUE is still present in the Athlete’s body. In such cases, the Anti-Doping Organization conducting the initial review of an adverse analytical finding will consider whether the finding is consistent with expiry or withdrawal of the TUE.]

  • 4.7 An application for a TUE will not be considered for retroactive approval except in cases where:

    • a. Emergency treatment or treatment of an acute medical condition was necessary, or

    • b. due to exceptional circumstances, there was insufficient time or opportunity for an applicant to submit, or a TUEC to consider, an application prior to Doping Control, or

    • c. the conditions set forth under 7.13 apply.

[Comment: Medical emergencies or acute medical situations requiring administration of an otherwise Prohibited Substance or Prohibited Method before an application for a TUE can be made, are uncommon. Similarly, circumstances requiring expedited consideration of an application for a TUE due to imminent competition are infrequent. Anti-Doping Organizations granting TUEs should have internal procedures which permit such situations to be addressed.]

5.0. Confidentiality of Information

  • 5.1 The applicant must provide written consent for the transmission of all information pertaining to the application to members of the TUEC and, as required, other independent medical or scientific experts, or to all necessary staff involved in the management, review or appeal of TUEs .

    Should the assistance of external, independent experts be required, all details of the application will be circulated without identifying the Athlete concerned. The applicant must also provide written consent for the decisions of the TUEC to be distributed to other relevant Anti-Doping Organizations under the provisions of the Code.

  • 5.2 The members of the TUECs and the administration of the Anti-Doping Organization involved will conduct all of their activities in strict confidence. All members of a TUEC and all staff involved will sign confidentiality agreements. In particular they will keep the following information confidential:

    • a. All medical information and data provided by the Athlete and physician(s) involved in the Athlete’s care.

    • b. All details of the application including the name of the physician(s) involved in the process.

    Should the Athlete wish to revoke the right of the TUEC or the WADA TUEC to obtain any health information on his/her behalf, the Athlete must notify his/her medical practitioner in writing of the fact. As a consequence of such a decision, the Athlete will not receive approval for a TUE or renewal of an existing TUE.

6.0 Therapeutic Use Exemption Committees (TUECs)

TUECs shall be constituted and act in accordance with the following guidelines:

  • 6.1 TUECs should include at least three (3) physicians with experience in the care and treatment of Athletes and a sound knowledge of clinical, sports and exercise medicine. In order to ensure a level of independence of decisions, the majority of the members of any TUEC should be free of conflicts of interest or political responsibility in the Anti-Doping Organization.

    All members of a TUEC will sign a conflict of interest agreement. In applications involving Athletes with disabilities, at least one TUEC member must possess specific experience with the care and treatment of Athletes with disabilities.

  • 6.2 TUECs may seek whatever medical or scientific expertise they deem appropriate in reviewing the circumstances of any application for a TUE.

  • 6.3 The WADA TUEC shall be composed following the criteria set out in Article 6.1. The WADA TUEC is established to review on its own initiative TUE decisions granted by Anti-Doping Organizations. As specified in Article 4.4 of the Code, the WADA TUEC, upon request by Athletes who have been denied TUEs by an Anti-Doping Organization, will review such decisions with the power to reverse them.

7.0 Therapeutic Use Exemption (TUE) Application Process

  • 7.1 A TUE will only be considered following the receipt of a completed application form that must include all relevant documents (see Annex 2 – TUE form). The application process must be dealt with in accordance with the principles of strict medical confidentiality.

  • 7.2 The TUE application form(s), as set out in Annex 2, can be modified by Anti-Doping Organizations to include additional requests for information, but no sections or items shall be removed.

  • 7.3 The TUE application form(s) may be translated into other language(s) by Anti-Doping Organizations, but English or French must remain on the application form(s).

  • 7.4 An Athlete may not apply to more than one Anti-Doping Organization for a TUE. The application must identify the Athlete’s sport and, where appropriate, discipline and specific position or role.

  • 7.5 The application must list any previous and/or current requests for permission to use an otherwise Prohibited Substance or Prohibited Method, the body to whom that request was made, and the decision of that body.

  • 7.6 The application must include a comprehensive medical history and the results of all examinations, laboratory investigations and imaging studies relevant to the application. The arguments related to the diagnosis and treatment, as well as duration of validity, should follow the WADA “Medical Information to Support the Decisions of TUECs”. For asthma, the specific requirement(s) set out in Annex 1 must be fulfilled.

  • 7.7 Any additional relevant investigations, examinations or imaging studies requested by the TUEC of the Anti-Doping Organization before approval will be undertaken at the expense of the applicant or his/her national sport governing body.

  • 7.8 The application must include a statement by an appropriately qualified physician attesting to the necessity of the otherwise Prohibited Substance or Prohibited Method in the treatment of the Athlete and describing why an alternative, permitted medication cannot, or could not, be used in the treatment of this condition.

  • 7.9 The dose, frequency, route and duration of administration of the otherwise Prohibited Substance or Prohibited Method in question must be specified. In case of change, a new application should be submitted.

  • 7.10 In normal circumstances, decisions of the TUEC should be completed within thirty (30) days of receipt of all relevant documentation and will be conveyed in writing to the Athlete by the relevant Anti-Doping Organization.

    In case of a TUE application made in a reasonable time limit prior to an Event the TUEC should use its best endeavors to complete the TUE process before the start of the Event. Where a TUE has been granted to an Athlete in the Anti-Doping Organization Registered Testing Pool, the Athlete and WADA will be provided promptly with an approval which includes information pertaining to the duration of the exemption and any conditions associated with the TUE.

  • 7.11

    • a. Upon receiving a request by an Athlete for review, the WADA TUEC will, as specified in Article 4.4 of the Code, be able to reverse a decision on a TUE denied by an Anti-Doping Organization. The Athlete shall provide to the WADA TUEC all the information for a TUE as submitted initially to the Anti-Doping Organization accompanied by an application fee. Until the review process has been completed, the original decision remains in effect. The process should not take longer than thirty (30) days following receipt of all the information by WADA.

    • b. WADA can, on its own initiative, undertake a review at any time.

  • 7.12 If the decision regarding the granting of a TUE is reversed by WADA upon review, the reversal shall not apply retroactively and shall not disqualify the Athlete's results during the period that the TUE had been granted and shall take effect no later than fourteen (14) days following notification of the decision to the Athlete.

  • 7.13 The Use of inhaled Beta-2 Agonists:

    • The Use of inhaled formoterol, salbutamol, salmeterol, terbutaline reflects current clinical practice. The Use of these substances should be declared on ADAMS where reasonably feasible and in accordance with the Code as soon as the product is used and must as well be declared on the Doping Control form at the time of Testing. Failure to declare will be taken into account in the result management process in particular in case of application for a Retroactive TUE.

    • Athletes using the substances listed above by inhalation must have a medical file justifying this Use and meeting the minimum requirements outlined in Annex 1.

Depending upon the category of the Athlete, the medical file will be evaluated as follows:

  • For all Athletes included in an International Federation Registered Testing Pool a regular TUE approved before the Use of the substance.

  • For Athletes participating in an International Event but who are not included in an International Federation Registered Testing Pool either a TUE, or a Retroactive TUE in the case of an Adverse Analytical Finding, in accordance with the rule of the International Federation or of the Major Event Organization.

  • For national-level Athletes who are not included in an International Federation Registered Testing Pool, whether or not they are part of a national Registered Testing Pool, either a TUE, or a Retroactive TUE in the case of an Adverse Analytical Finding, in accordance with the rules of the National Anti-Doping Organization.

  • No Retroactive TUE will be granted if the requirements of Annex 1 are not met meaning that any Adverse Analytical Finding reported by laboratory in these circumstances will result in an anti-doping rule violation.

  • Any Athlete may apply for a TUE at any time if they wish.

  • Any Athlete who has applied for a TUE or a Retroactive TUE and who was denied such TUE may not use the substance without the prior granting of a TUE (no Retroactive TUE will be permitted).

8.0 Declaration of Use Process

  • 8.1 It is acknowledged that some substances included on the List of Prohibited Substances are used to treat medical conditions frequently encountered in the athlete population. For monitoring purposes, these substances, for which the route of administration is not prohibited, will require a simple declaration of use. These are strictly limited to:

    Glucocorticosteroids used by non systemic routes, namely intraarticular, periarticular, peritendinous, epidural, intradermal injections and inhaled route.

  • 8.2 For the mentioned substances, the declaration of Use should be done through ADAMS where reasonably feasible and in accordance with the Code by the Athlete at the same time as the Use starts. This declaration should mention the diagnosis, the name of the substance, the dose undertaken, the name and the contact details of the physician.

    In addition, the Athlete must declare the Use of the substance in question on the Doping Control form.

9.0 Clearinghouse

  • 9.1 Anti-Doping Organisations are required to provide WADA with all TUEs approved for Athletes who are part of a national or international Registered Testing Pool, and all supporting documentation, in accordance with section 7.

  • 9.2 The declarations of use should be available to WADA (ADAMS).

  • 9.3 The clearinghouse shall guarantee strict confidentiality of all the medical information.

10.0 Transitional provision

Abbreviated Therapeutic Use Exemptions (ATUEs) delivered prior to December 31, 2008 shall remain governed by the 2005 TUE Standard.

These ATUEs shall remain valid after January 1, 2009 until the earliest of:

  • (i) The date on which they are cancelled by the competent TUEC following review in accordance with art. 8.6 of the 2005 TUE Standard;

  • (ii) Their expiry date as mentioned on the ATUE;

  • (iii) December 31, 2009.


C. VERTALING

Zie Trb. 2006, 194.

Voor een correctie in de vertaling zie Trb. 2007, 5.

D. PARLEMENT

Zie Trb. 2007, 5.

E. PARTIJGEGEVENS

Zie Trb. 2006, 194.

Partij

Ondertekening

Ratificatie

Type*

In werking

Opzegging

Buiten werking

Albanië

 

31-12-06

T

01-02-07

   

Algerije

 

29-12-06

R

01-02-07

   

Argentinië

 

29-12-06

R

01-02-07

   

Australië

 

17-01-06

R

01-02-07

   

Azerbeidzjan

 

23-07-07

T

01-09-07

   

Bahama's

 

12-10-06

R

01-02-07

   

Bangladesh

 

22-10-07

R

01-12-07

   

Barbados

 

21-12-06

R

01-02-07

   

België

 

19-06-08

R

01-08-08

   

Bolivia

 

15-11-06

R

01-02-07

   

Brazilië

 

18-12-07

R

01-02-08

   

Brunei

 

31-03-08

R

01-05-08

   

Bulgarije

 

12-01-07

R

01-03-07

   

Burkina Faso

 

12-11-08

R

01-01-09

   

Burundi

 

05-09-07

R

01-11-07

   

Cambodja

 

09-04-08

T

01-06-08

   

Canada

 

29-11-05

R

01-02-07

   

China

 

09-10-06

T

01-02-07

   

Cook-eilanden

 

15-02-06

T

01-02-07

   

Cuba

 

28-07-08

T

01-09-08

   

Denemarken

 

15-12-05

R

01-02-07

   

Duitsland

 

31-05-07

R

01-07-07

   

Ecuador

 

22-03-07

T

01-05-07

   

Egypte

 

23-05-07

R

01-07-07

   

El Salvador

 

05-09-08

T

01-11-08

   

Eritrea

 

19-08-08

R

01-10-08

   

Estland

 

17-08-07

R

01-10-07

   

Ethiopië

 

30-07-08

R

01-09-08

   

Finland

 

22-12-06

R

01-02-07

   

Frankrijk

 

05-02-07

R

01-04-07

   

Gabon

 

27-11-07

R

01-01-08

   

Ghana

 

31-12-06

R

01-02-07

   

Griekenland

 

31-12-06

R

01-02-07

   

Guatemala

 

17-03-08

R

01-05-08

   

Hongarije

 

29-08-07

R

01-10-07

   

Ierland

 

18-07-08

R

01-09-08

   

IJsland

 

10-02-06

T

01-02-07

   

India

 

07-11-07

R

01-01-08

   

Indonesië

 

30-01-08

R

01-03-08

   

Italië

 

27-02-08

R

01-04-08

   

Ivoorkust

 

29-07-08

R

01-09-08

   

Jamaica

 

02-08-06

R

01-02-07

   

Japan

 

26-12-06

R

01-02-07

   

Kaapverdië

 

05-06-08

R

01-08-08

   

Kameroen

 

15-10-07

T

01-12-07

   

Koeweit

 

13-07-07

T

01-09-07

   

Kroatië

 

03-10-07

R

01-12-07

   

Letland

 

10-04-06

T

01-02-07

   

Libië

 

30-05-07

R

01-07-07

   

Litouwen

 

02-08-06

R

01-02-07

   

Luxemburg

 

11-12-06

R

01-02-07

   

Macedonië, Voormalige Joegoslavische Republiek

 

09-10-08

R

01-12-08

   

Maleisië

 

20-12-06

R

01-02-07

   

Mali

 

30-05-07

R

01-07-07

   

Mauritius

 

06-07-06

R

01-02-07

   

Mexico

 

11-04-07

R

01-06-07

   

Moldavië

 

19-02-08

R

01-04-08

   

Monaco

 

30-01-06

R

01-02-07

   

Mongolië

 

15-10-07

T

01-12-07

   

Mozambique

 

23-10-06

R

01-02-07

   

Namibië

 

29-11-06

R

01-02-07

   

Nauru

 

04-05-06

R

01-02-07

   

Nederlanden, het Koninkrijk der

           

– Nederland

 

17-11-06

R

01-02-07

   

– Ned. Antillen

 

 

   

– Aruba

 

11-07-08

R

01-09-08

   

Nieuw-Zeeland

 

23-12-05

R

01-02-07

   

Niger

 

26-10-06

R

01-02-07

   

Nigeria

 

24-02-06

R

01-02-07

   

Noorwegen

 

13-01-06

R

01-02-07

   

Oekraïne

 

08-11-06

R

01-02-07

   

Oman

 

09-07-07

R

01-09-07

   

Oostenrijk

 

19-07-07

R

01-09-07

   

Pakistan

 

04-02-08

R

01-04-08

   

Palau

 

23-09-08

T

01-11-08

   

Panama

 

27-11-07

R

01-01-08

   

Paraguay

 

13-10-08

R

01-12-08

   

Peru

 

16-10-06

R

01-02-07

   

Polen

 

17-01-07

T

01-03-07

   

Portugal

 

30-04-07

R

01-06-07

   

Qatar

 

24-08-07

R

01-10-07

   

Roemenië

 

23-10-06

R

01-02-07

   

Russische Federatie

 

29-12-06

R

01-02-07

   

Samoa

 

08-08-07

R

01-10-07

   

Saudi-Arabië

 

22-05-08

T

01-07-08

   

Senegal

 

29-04-08

R

01-06-08

   

Seychellen, de

 

05-07-06

R

01-02-07

   

Singapore

 

05-11-07

T

01-01-08

   

Sint Kitts en Nevis

 

14-04-08

R

01-06-08

   

Sint Lucia

 

07-12-07

R

01-02-08

   

Slovenië

 

18-09-08

T

01-11-08

   

Slowakije

 

26-01-07

R

01-03-07

   

Spanje

 

25-10-06

R

01-02-07

   

Thailand

 

15-01-07

R

01-03-07

   

Trinidad en Tobago

 

09-03-07

T

01-05-07

   

Tsjaad

 

10-10-08

R

01-12-08

   

Tsjechië

 

30-04-07

R

01-06-07

   

Tunesië

 

26-12-06

R

01-02-07

   

Uganda

 

27-10-08

R

01-12-08

   

Uruguay

 

28-04-08

R

01-06-08

   

Verenigd Koninkrijk, het

 

25-04-06

R

01-02-07

   

Verenigde Staten van Amerika, de

 

25-08-08

R

01-10-08

   

Zuid-Afrika

 

30-11-06

R

01-02-07

   

Zuid-Korea

 

05-02-07

R

01-04-07

   

Zweden

 

09-11-05

R

01-02-07

   

Zwitserland

 

23-10-08

T

01-12-08

   

* O=Ondertekening zonder voorbehoud of vereiste van ratificatie, R= Bekrachtiging, aanvaarding, goedkeuring of kennisgeving, T=Toetreding, VG=Voortgezette gebondenheid, NB=Niet bekend

Uitbreidingen

China

Uitgebreid tot

In werking

Buiten werking

Hong Kong SAR

01-02-2007

 

Macau SAR

01-02-2007

 

Verenigd Koninkrijk, het

Uitgebreid tot

In werking

Buiten werking

Alderney

01-02-2007

 

Bermuda

01-02-2007

 

Cayman-eilanden

01-02-2007

 

Falkland-eilanden

01-02-2007

 

Guernsey

01-02-2007

 

Jersey

01-02-2007

 

Man

01-02-2007

 
Verklaringen, voorbehouden en bezwaren

Argentinië, 29 december 2006

The Argentine Republic rejects the claim to extend to the Falkland Islands the application of the International Convention against Doping in Sport, adopted in Paris on 19 October 2005 by the General Conference of UNESCO, notified to the Director-General of UNESCO by the United Kingdom of Great Britain and Northern Ireland on 25 April 2006, and reaffirms its rights of sovereignty over the integral part of its national territory and, being illegaly occupied by the United Kingdom of Great Britain and Northern Ireland, are the subject of a sovereignty dispute between the two countries, which has been recognized by several international organizations.

In this regard, the General Assembly of the United Nations, adopted resolutions 2065 (XX), 3160 (XXVIII), 31/49, 37/9, 38/12, 39/6, 40/21, 41/40, 42/19 and 43/25, in which it recognized the existence of a dispute over sovereignty in relation to the question of the Falkland Islands and urged the Argentine Republic and the United Kingdom of Great Britain and Northern Ireland to initiate negotiations with a view to finding a peaceful and lasting solution to the sovereignty dispute as soon as possible. For its part, the Special Committee on Decolonisation of the United Nations had repeatedly made similar appeals, most recently in de resolution adopted on 15 June 2006. Similarly, the General Assembly of the Organization of American States adopted a new resolution on the subject on 6 June 2006.

Denemarken, 15 december 2005

Unless so decided at a later date the Convention shall not apply to the Faroe Islands and Greenland.

Nieuw-Zeeland, 23 december 2005

AND DECLARES that, consistent with the constitutional status of Tokelau and taking into account the commitment of the Government of New Zealand to the development of self-government for Tokelau through an act of self-determination under the Charter of the United Nations, this acceptance shall not extend to Tokelau unless and until a Declaration to this effect is lodged by the Government of New Zealand with the Depositary on the basis of appropriate consultation with that territory.

Verenigde Staten van Amerika, de, 25 augustus 2008

The Senate of the United States of America by its resolution of July 21, 2008, two-thirds of the Senators present concurring therein, gave its advice and consent to ratification of the Convention subject to the following understanding:

It is the understanding of the United States of America that nothing in this Convention obligates the United States to provide funding to the World Anti-Doping Agency.

The Senate’s advice and consent is subject to the following declaration:

Pursuant to Article 2 (4), which defines “Athlete” for purposes of doping control as “any person who participates in sport at the international or national level as defined by each national anti-doping organization and accepted by States Parties and any additional person who participates in a sport or event at a lower level accepted by States Parties”, the United States of America declares that “Athlete” for purposes of doping control means any athlete determined by the U.S. Anti-Doping Agency to be subject to or to have accepted the World Anti-Doping Code.

G. INWERKINGTREDING

Zie Trb. 2007, 5 en Trb. 2008, 176.

De wijzigingen van Bijlage I (zie Trb. 2009, 24) en van Bijlage II bij het Verdrag zijn ingevolge artikel 34, derde lid, op 1 januari 2009 in werking getreden.

J. VERWIJZINGEN

Zie Trb. 2006, 194, Trb. 2007, 5 en Trb. 2008, 176.

Titel

:

Overeenkomst ter bestrijding van doping;

Straatsburg, 16 november 1989

Laatste Trb.

:

Trb. 2009, 24

In overeenstemming met artikel 19, tweede lid, van de Rijkswet goedkeuring en bekendmaking verdragen heeft de Minister van Buitenlandse Zaken bepaald dat de wijzigingen van Bijlage II van 10 mei 2008 en 20 september 2008 zullen zijn bekendgemaakt in Nederland en Aruba op de dag na de datum van uitgifte van dit Tractatenblad.

Uitgegeven de zevenentwintigste februari 2009.

De Minister van Buitenlandse Zaken,

M. J. M. VERHAGEN


XNoot
1)

De bijlagen bij Bijlage II liggen ter inzage bij de Afdeling Verdragen van het Ministerie van Buitenlandse Zaken en zijn te vinden op http://www.wada-ama.org.

Naar boven